Read K101956.pdf text version

# shuumann

510(k) SUMMARY

DEC 16 2010

A. Submitter's Information

Name: Address: Phone: Fax Number: Contact Person:

Straumann US (on behalf of Institut Straumann AG) 60 Minuteman Road Andover, MA 01810 (800) 448-8168, ext 2575 978-747-0023 Janet C. Kay, Director Regulatory Affairs

B. Date Summary Prepared: August 17, 2010

C. Device Name: Propriety Name: Common/Usual Name: Classification Name: Classification Number: Product Code/Review Panel D. Predicate Device Name: Straumann MembraGel Bone grafting material Barrier, Synthetic, Intraoral Class 11 Part 872.3930 NPK

* Straumann MembraGel (K082111, 5/22/09)

E. Description of the Device

Straumann® MembraGel is a sterile, synthetic, degradable barrier membrane for single patient use. It is composed of two liquid poly(ethylene glycol) (PEG) compounds forming a hydrogel upon mixing. Straumann MembraGel is applied as a viscous liquid and gels on the application site within approximately 20 to 50 seconds. Straumann MembraGel acts as a barrier that inhibits non-osteogenic soft tissue cells of the overlying soft tissue from entering the defect site thereby supporting undisturbed regeneration of alveolar bone. Degradation of

August 24, 2010

Straumann USA

Page 59 of 89

Straumann MembraGel by hydrolysis starts during normal wound healing. Straumann MembraGel must be stored refrigerated between 2-81C (36-461F). The application volume of Straumann MembraGel is 0.8 ml for approximately 57cm2 coverage.

The Straumann MembraGel kit contains: 1. Two glass syringes each filled with a PEG component (PEG A and PEG B) mounted in a plastic holder. 2. Two plastic syringes each filled with an activator (Activator A and Activator B) in a plastic holder. 3. One applicator tip (a static mixer connected to an adapter). All components are delivered sterile and must be used immediately after opening of the blister packaging in an aseptic surgical environment. See Instructions for use handling instructions. F. Intended Use of the Device Straumann MembraGel is a biodegradable, synthetic, in situ forming hydrogel material. It is intended to aid in the regeneration and integration of oral tissue components in guided bone regeneration procedures. This includes the surgical treatment of peni-implant defects, bone defects, deficient alveolar ridges, and extraction sockets. Because MembraGel is not self-supporting, it must be used in combination with a bone graft material in order to maintain space under the membrane.

G. Technological Characteristics The proposed device is substantially equivalent to currently marketed device. The intended use is the same as the intended use of the predicate device. The proposed MembraGel has the same design and fundamental operating principles as the predicate device. The changes to the material composition had no impact to the final design of the product and remains substantially equivalent to the predicate device, Table 1.demonstrates the technological modifications made to MembraGel compared to the currently marketed predicate device.

August 24, 2010

Straumann USA

Page 60 of 89

Table 1

4 Srdfumdfn

FetrsMbdifiUd Sti'aumann MembraselL

MehibraGel'>.

Operating Principle Physical

Properties

Straumann MembraGel is applied on the site in liquid form through a syringe applicator Initial swelling of Straumann MembraGel

samples meet internal specifications

Identical Identical

Tissue Occlusive Properties

Gelation time of the Straumann® MembraGel kit between 20 and 50s A degradation pattern meets internal specifications including complete degradation of the Straumann MembraGel. Identical Tissue occlusive properties depend on the physical properties of the PEG network, which is governed density of the crosslink. Cell occiusivity is determined by the degradation pattern and time. Thus, tissue occlusive properties were not impacted by this modification. The viscosity of the formulation is determined by the Activators present in solution A and B. These solutions were not impacted by the modification described in this 510(k) Identical

Viscosity

Wate upakeThe modified device was required to meet the original specification of te geled

Identical

H. Performance Testing

Verification and validation testing were performed to ensure that the Straumann MembraGel functions as intended and that the modification did not impact the essential performance of the MembraGel. The Table 2 describes the testing performed on the MembraGel included:

August 24, 2010

Straumann USA

Page 61 of 89

kici95&

Table 2 Test performed Acceptance criteria .$ Biocompatibility measurements results equal CytotoicityCytotoxic than the predicate Cytotoicityto or less Acute Systemic Toxicity results equal to or less than the predicate SQ Implantation results equal to or less than the predicate Results

15riLt:2<.~t~r.

Non-cytotoxic Non-toxic Slight Irritant' Passed Passed Passed

________

Acute Systemic Toxicity SQ Implantation (4 Weeks) - Rabbits

20-50 sec Gelation time Less than 200%wt within 4h after In-vitro water uptake of the gelled gelation product InviroderaatonFollowing a defined degradation In-vtro dandation kinetics ending in complete disintegration of the MembraGel patten andtime 'Response noted was typical for similar absorbable materials implanted

subcutaneously

1. Conclusion The results from the testing conducted, demonstrated that the Straumann MembraGel functions as intended and met pre-determined acceptance criteria. The Straumann MembraGel is a validated system. The results of performance testing, biocompatibility testing, and risk analysis indicate that the Straumann MembraGel is substantially equivalent to the named predicate device.

August 24, 2010

Straumann USA

Page 62 of 89

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration 10903 Newv Hampshire Avenue Document Control Room -W066-G609 Silver Spring, MD 20993-0002

Ms. Janet C. KayDE1620

Director, Regulatory Affairs Straumann USA 60 Minuteman Road Andover, Massachusetts 0 18 10

Re: K101956

Trade/Device Name: Straumann MembraGelT

Regulation Number: 21 CFR 872.3930 Regulation Name: Bone Grafting Material Regulatory Class: 11 Product Code: NPK Dated: December 6, 2010 Received: December 7, 20 10

Dear Ms. Kay: We have reviewed your Section 5 10(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class 11 (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 2 1, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Page 2- Ms. Kay

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CER Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CER 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CER Part 820); and if applicable, the electronic product radiation control provisions (Sections 53 1-542 of the Act); 21 CER 1000- 1050. If you desire specific advice for your device on our labeling regulation (21 CER Part 80 1), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDR}IOffices/ucm I I 5809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (2 1CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH' s Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general intormation on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.g2ov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours,

Anthony D. Watson, B.S., M.S., M.B.A. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Straumann® MembraGell Special 510(k) Notification Indications for Use Statement

510(k) Number (if known) Device Name: Straumann MembraGeTM

Indications far Use:

Straumann MembraGel is a biodegradable, synthetic, in situ forming hydrogel material. It is intended to aid in the regeneration and integration of oral tissue components in guided bone regeneration procedures. This includes the surgical treatment of peni-implant defects, bone defects, deficient alveolar ridges, and extraction sockets. Because MembraGel is not self-supporting, it must be used in combination with a bone graft material in order to maintain space under the membrane.

Prescription Use ___X__ (Part 21 CFR 801 Subpart D)

AND/OR

Over the Counter Use (21 CFR 807 Subpart C)

__

PLEASE DO, NOT WRITE BELOW THIS. LINE PAGE IF NEEDED

-

CONTINUE ON ANOTHER

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off) Division of Anesthesiology, General Hospital Infection Control, Dental Devices

510(k) Number:

___________

July 9, 2010

Straumann USA

Page 53 of 85

Information

7 pages

Find more like this

Report File (DMCA)

Our content is added by our users. We aim to remove reported files within 1 working day. Please use this link to notify us:

Report this file as copyright or inappropriate

201468


You might also be interested in

BETA